Blog
RSS FeedPosted by Michael Wonder on 05 Sep 2016
Australian Statistics on Medicines 2015
5 September 2016 - The Australian Statistics on Medicines for 2015 are now available. ...
Posted by Michael Wonder on 05 Sep 2016
Eisai bewildered as Germany's IQWIG fails to recognise additional benefit of Halaven (eribulin mesylate) in the treatment of advanced liposarcoma
4 September 2016 - Assessment ignores unprecedented overall survival benefit for eribulin in advanced liposarcoma. ...
Posted by Michael Wonder on 05 Sep 2016
PHARMAC’s implementation of Trans-Pacific Partnership provisions and other amendments to application processes
5 September 2016 - PHARMAC is seeking feedback on our proposed approach to addressing New Zealand’s obligations under the Trans-Pacific Partnership ...
Posted by Michael Wonder on 05 Sep 2016
Proposal related to second & third-line anti-VEGF treatments for ophthalmic use
5 September 2016 - PHARMAC has entered into provisional agreements with Novartis and Bayer and is seeking feedback on a ...
Posted by Michael Wonder on 05 Sep 2016
Help shape the way PHARMAC implements TPP changes
5 September 2016 - PHARMAC is asking New Zealanders to help it make some changes to how medicine and medical device ...
Posted by Michael Wonder on 03 Sep 2016
NICE recommends Cancer Drugs Fund treatment for prostate cancer for routine NHS use
2 September 2016 - More prostate cancer patients will receive radium 223 after NICE approved it for routine NHS use. ...
Posted by Michael Wonder on 01 Sep 2016
Elotuzumab in multiple myeloma: additional clinical benefit is not proven
1 September 2016 - The only study available was unsuitable for the benefit assessment. ...
Posted by Michael Wonder on 01 Sep 2016
Live national webcast of review of pharmacy remuneration and regulation
1 September 2016 - The review panel will host a live national webcast from Canberra on 7 September 2016 at 7:00pm ...
Posted by Michael Wonder on 31 Aug 2016
Q&A: Is NZ lagging in cancer drug funding?
31 August 2016 - Researchers have called for an urgent overhaul of New Zealand's processes for funding cancer drugs to ensure ...
Posted by Michael Wonder on 31 Aug 2016
Schedule of Pharmaceutical Benefits - 1 September 2016 update
1 September 2016 - The 1 September 2016 issue of the Schedule of Pharmaceutical Benefits sees a number of new ...
Posted by Michael Wonder on 31 Aug 2016
New Zealand Pharmaceutical Schedule - 1 September 2016 update
1 September 2016 - The September 2016 issue of the New Zealand Pharmaceutical Schedule sees the listing of one new ...
Posted by Michael Wonder on 30 Aug 2016
Agenda for the 7 September 2016 TC meeting
30 August 2016 - The Transparency Commission will reconvene early next month after the summer break to review a few new ...
Posted by Michael Wonder on 30 Aug 2016
Decision to award sole supply to Zoladex and reference price Eligard and Lucrin
30 August 2016 - PHARMAC has made decisions to award the Zoladex brand of goserelin acetate sole subsidised supply in the ...
Posted by Michael Wonder on 30 Aug 2016
CADTH recommends Brilinta (ticagrelor)
25 August 2016 - CADTH has recommended the reimbursement of AstraZeneca's Brilinta (ticagrelor) for the secondary prevention of atherothrombotic events. ...
Posted by Michael Wonder on 30 Aug 2016
CADTH recommends the reimbursement of Invokamet (canagliflozin hemihydrate with metformin hydrochloride)
25 August 2016 - CADTH has published its final recommendation on the reimbursement of Invokamet in Canada. ...